Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita 879-5593, Japan.
Clin Chim Acta. 2013 Sep 23;424:119-22. doi: 10.1016/j.cca.2013.05.025. Epub 2013 Jun 6.
Therapeutic drug monitoring (TDM) of voriconazole is important to optimize efficacy and to minimize toxicity and intolerance. In this study, we evaluated the effect of sustained high plasma trough concentration of voriconazole on the incidence of hepatotoxicity in hospitalized Japanese patients.
Thirty-nine patients were divided into 3 groups according to trough concentrations in two consecutive TDMs: <4 μg/ml in the first TDM (group A, n=25), >4 μg/ml in the first and <4 μg/ml in the second TDM (group B, n=8), and >4 μg/ml in both first and second TDMs (group C, n=6).
Incidences of hepatotoxicity in groups A, B and C were 16.0, 25.0 and 83.3%, and significant differences were observed between groups A and C and groups B and C. Multiple logistic regression analysis identified the classification into groups A, B and C as an independent variable of hepatotoxicity.
These results suggest that sustained high trough concentration of voriconazole may increase the risk of hepatotoxicity, and decreasing trough concentration to <4 μg/ml by dose adjustment after the initial TDM may reduce the incidence of hepatotoxicity in patients treated with voriconazole.
伏立康唑的治疗药物监测(TDM)对于优化疗效、最小化毒性和不耐受性非常重要。本研究评估了伏立康唑持续高血浆谷浓度对住院日本患者肝毒性发生率的影响。
39 名患者根据两次连续 TDM 的谷浓度分为 3 组:第一次 TDM<4μg/ml(组 A,n=25)、第一次>4μg/ml 且第二次<4μg/ml(组 B,n=8)、两次 TDM 均>4μg/ml(组 C,n=6)。
组 A、B 和 C 的肝毒性发生率分别为 16.0%、25.0%和 83.3%,组 A 与 C 之间以及组 B 与 C 之间差异有统计学意义。多变量逻辑回归分析表明,分组为 A、B 和 C 是肝毒性的独立变量。
这些结果表明,伏立康唑持续高谷浓度可能会增加肝毒性的风险,通过初始 TDM 后调整剂量将谷浓度降低至<4μg/ml 可能会降低伏立康唑治疗患者的肝毒性发生率。